Lv5
830 积分 2023-10-28 加入
First-In-Human [177Lu]Lu-FAPI-XT Therapy Combined With Anti-PD-1 Antibody in a Patient With Metastatic Colon Cancer Who Has Progressed on Multiple Prior Lines of Therapy
1天前
求助中
Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy
1个月前
已关闭
Therapeutic Efficacy of Neoadjuvant Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
1个月前
已关闭
Adaptations of neutrophils in cancer
4个月前
已完结
From complexity to consensus: A roadmap for neutrophil classification
4个月前
已完结
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force
7个月前
已完结
Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study
7个月前
已完结
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O 6 -Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)
8个月前
已完结
MRI-based Habitat Imaging for Noninvasive Prediction of High-Grade Prostate Cancer
8个月前
已完结
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
1年前
已完结
皖公网安备34019202002308
